Message from the Guest Editor

Dear Colleagues,

The unmet needs in prostate cancer diagnosis and therapy are diverse; there is an urgent need for biomarkers that can be used for the early diagnosis of patients with clinically significant prostate cancer. Significant steps forward are made and are reviewed in this issue. Once metastasized, there is still no effective treatment, let stand alone a curative therapy. A better understanding of sustained androgen receptor signaling in CRPC has now led to more effective therapies. Apart from a better insight in the molecular aspects of prostate carcinogenesis and -progression, we need to understand the tumor cell biology. Identification of cancer initiating cells and therapies targeted to eradicate these population(s) are the way forward to combat this disease.

Prof. Dr. Jack A. Schalken
Guest Editor

Author Benefits

Open Access: free for readers, with publishing fees paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science), MEDLINE (PubMed) and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 22 days after submission; acceptance to publication is undertaken in 8 days (median values for 2016).